Implications of nonadherence for economic evaluation and health policy

Patient Treatment Adherence: Concepts, Interventions, and Measurement

Volumn , Issue , 2005, Pages 421-451

  Van Houtven, Courtney Harold ^a   Weinberger, Morris ^b   Carey, Tim ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904824519     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9781410615626     Document Type: Chapter

References (47)

1. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother. 1993;27(Suppl):1-24.
2. Iskedjian M, Addis A, Einarson TR. Estimating the economic burden of hospitalization due to patient nonadherence in Canada. In: 1998 International Society for Pharmaceutical and Outcomes Research Conference. 1998.
3. Haynes R, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions of medications. (Cochrane Review). In: The Cochrane Library. 2003.
4. Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. Lancet. 2002;359(9324):2129-2130.
5. Swindle RW, Rao JK, Helmy A, et al. Integrating clinical nurse specialists into the treatment of primary care patients with depression. Int J Psychiatry Med. 2003;33:17-37.
6. Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens. 2001;19(Suppl 3):33-40.
7. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 2001;10:601-615.
8. Leibowitz A, Manning WG Jr., Newhouse JP. The demand for prescription drugs as a function of cost sharing. Soc Sci Med. 1985;21:1063-1070.
9. Case A, Lubotsky D, Paxon C. Economic status and health in childhood: the origins of the gradient. American Economic Review. 2001;92(5):1308-1334.
10. Ashton C, Haidet P, Pateniti DA, et al. Racial and ethnic disparities in the use of health services: bias, preferences, or poor communication? J Gen Intern Med. 2003;18(2):146-152.
11. Gosden T, Forland F, Kristiansen IS, et al. Impact of payment method on behaviour of primary care physicians: a systematic review. Journal of Health Services Research Policy. 2001;6(1):44-55.
12. Green JH. Frequent rehospitalization and noncompliance with treatment. Hospital Community Psychiatry. 1988;39(9):963-966.
13. Fishbein HA. Precipitants of hospitalization in insulin-dependent diabetes mellitus (IDDM): a statewide perspective. Diabetes Care. 1985;8(Suppl 1):61-64.
14. Singer ME. Medical and economic outcomes of noncompliance with dilantin in adult Medicaid epileptics. Value Health. 1998;1(1):47.
15. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. New York: Oxford Medical Publications; 1997.
16. Gold MR, Siegel JE, Rossell LB, et al. Cost-Effectiveness in Health and Medicine. Weinstein M, ed. New York: Oxford University Press; 1996.
17. Johannesson M. Theory and Methods of Economic Evaluation of Health Care. Dordrecht, the Netherlands: Kluwer Academic Publishers; 1996.
18. Sloan FA, ed. Valuing Health Care: Care, Costs and Benefits of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press; 1995.
19. Van Houtven G. Lecture Notes on Economic Evaluation Methods. In: Marisa Domino's health economics course. University of North Carolina; 2003.
20. McIntosh E, Donaldson C, Ryan M. Recent advances in the methods of cost-benefit analysis in healthcare. Pharmacoeconomics. 1999;15(4):357-367.
21. Goldstein MK. Introduction to patient preferences and utility assessment. In: Health Economics Research Group Health Economics Research Course. Menlo Park, CA: VA Palo Alto Health Care System; 2003.
22. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care. 1992;30:473-483.
23. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;June 23:203-235.
24. Brazier J, Deverill M, Green C. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3(9):i-ix;1-164.
25. Weeks J, O'Leary J, Fairclough D, et al. The Q-tility Index: a new tool for assessing healthrelated quality of life and utilities in clinical trials and clinical practice. Proceedings of the American Society of Clinical Oncology. 1994;13:436.
26. American Thoracic Society. Quality of Life Indicators. http://www.thoracic.org.
27. McDowell I, Newell C. Measuring Health: A Guide to Rating Scales and Questionnaires. 2nd ed. New York: Oxford University Press; 1996.
28. Donaldson C. Valuing the benefits of publicly provided health care: does "ability to pay" preclude the use of "willingness to pay"? Soc Sci Med. 1999;49(4): 551-563.
29. O'Brien B, Viramontes J. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Mak. 1994;14(3):290-297.
30. Hirth RA, Chernew ME, Miller EA, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Mak. 2000;20(3):332-342.
31. Donaldson C. Eliciting patients' values by the use of "willingness to pay": letting the theory drive the method. Health Expect. 2001;4(3):180-188.
32. Goldstein MK, Michelson DG, Clarke AE, et al. A multimedia preferenceassessment tool for functional outcomes. In: 17th Annual Symposium on Computer Applications in Medical Care. New York: McGraw-Hill; 1993.
33. Lenert L, Kaplan RM. Validity and interpretation of preference-based measures of health-related quality of life. Med Care. 2000;38(Suppl 9):138-150.
34. Keilhorn A, Graf von der Schulenburg JM. The Health Economics Handbook. 2nd ed. Chester: Adis International; 2000.
35. Macarthur initiative on depression and primary care at Dartmouth and Duke Web sites. Respect-depression randomized controlled trial.
36. Toronto General Hospital. http://uhn.ca/tgh/.
37. Hyperdictionary. http://www.hyperdictionary.com.
38. Whittington D, Matsui O, Freiberger J, Van Houtven G, Pattanayak S. Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico. Vaccine. 2002;20(19/20):2585-2591.
39. Blandford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class, prescribing physician. J Manag Care Pharm. 1999;5(1):47-51.
40. Bronder E, Klimpel A. Unused drugs returned to the pharmacy-new data. Int J Clin Pharmacol. 2001;39(11):480-483.
41. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination anti-retroviral therapy for HIV disease. N Engl J Med. 2001;344(11):824-831.
42. Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med. 1997;201(2A):43-49.
43. Simes J, Furburg CD, Braunwald E, et al. Effect of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling Project. Eur Heart J. 2001;23: 207-215.
44. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study. Circulation. 1998;97:1453-1460.
45. Rosser WW. Application of evidence from randomized controlled trials to general practice. Lancet. 1999;353:661-664.
46. Avery S. NC aid for HIV will run short: state to put people on a waiting list. In: News and Observer. 2003.
47. Luce BR, Manning WG, Siegel JE, et al. Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.